



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

**Public Summary**

<b>Summary for ARTG Entry:</b>	323887	Hairpro
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	McPherson's Consumer Products Pty Ltd	
<b>Postal Address</b>	Locked Bag 5018, Kingsgrove, NSW, 2208 Australia	
<b>ARTG Start Date</b>	21/09/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1 . Hairpro**

Product Type	Single Medicine Product	Effective Date	1/10/2019
--------------	-------------------------	----------------	-----------

**Permitted Indications**

- Traditionally used in Chinese medicine to invigorate/activate Blood
- Traditionally used in Chinese medicine to nourish/tonify/warm/boost/invigorate/strengthen kidney-essence/kidney-jing
- Traditionally used in Chinese medicine to clear/disperse/expel/dissipate/cool blood-heat
- Traditionally used in Chinese medicine to longevity tonic
- Traditionally used in Chinese medicine to aid/assist/help/maintain healthy hair follicles
- Traditionally used in Chinese medicine to enhance/improve/promote/increase hair growth
- Traditionally used in Chinese medicine to enhance/improve/promote/increase hair health
- Traditionally used in Chinese medicine to decrease/reduce hair loss/thinning
- Traditionally used in Chinese medicine to helps enhance/promote healthy blood circulation
- Traditionally used in Chinese medicine to blood tonic/Enhance blood health
- Traditionally used in Chinese medicine to decrease/reduce/relieve scalp itching/irritation/redness

**Indication Requirements**

- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.
- Product presentation must not imply or refer to mental illnesses, disorders or conditions.
- If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.
- Product presentation must not imply or refer to serious cardiovascular conditions.
- Product presentation must not imply or refer to serious conditions associated with alopecia e.g. autoimmune disease, chemotherapy.

Public Summary



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Product presentation must not imply or refer to kidney disease.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

No Warnings included on Record

**Additional Product information**

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Angelica polymorpha root Extract dry concentrate</b>	<b>83.33 mg</b>
Equivalent: Angelica polymorpha (Dry)	1.25 g
<b>Biota orientalis twig leafy Extract dry concentrate</b>	<b>150 mg</b>
Equivalent: Biota orientalis (Dry)	1.5 g
<b>Cuscuta hygrophilae seed Extract dry concentrate</b>	<b>60.7 mg</b>
Equivalent: Cuscuta hygrophilae (Dry)	425 mg
<b>Glycyrrhiza uralensis root and stolon Extract dry concentrate</b>	<b>35 mg</b>
Equivalent: Glycyrrhiza uralensis (Dry)	175 mg
<b>Ligusticum striatum root Extract dry concentrate</b>	<b>35 mg</b>
Equivalent: Ligusticum striatum (Dry)	350 mg
<b>Paeonia lactiflora root Extract dry concentrate</b>	<b>70 mg</b>
Equivalent: Paeonia lactiflora (Dry)	490 mg
<b>Rehmannia glutinosa root Extract dry concentrate</b>	<b>41.7 mg</b>
Equivalent: Rehmannia glutinosa (Dry)	250.2 mg
<b>Rehmannia glutinosa root Extract dry concentrate</b>	<b>35.7 mg</b>
Equivalent: Rehmannia glutinosa (Dry)	250 mg

**Other Ingredients (Excipients)**

colloidal anhydrous silica

hypromellose

magnesium stearate

maltodextrin

microcrystalline cellulose

purified water

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.